close
Add to watchlist
Cytrx Corp (CYTR) Healthcare, Biotechnology & Drugs
CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II clinical development for the treatment of cancer; Bafetinib, a drug in Phase I clinical development to treat chronic myeloid leukemia; Arimoclomol, an orally-administered small-molecule product candidate in Phase IIb clinical development for the treatment of amyotrophic lateral sclerosis; and Iroxanadine, an orally-administered small-molecule product candidate in Phase I clinical development to treat diabetic ulcers. The company also engages in developing treatments for neurodegenerative and other disorders based on its small-molecule molecular chaperone amplification technology; and new-drug discovery research utilizing its master chaperone regulator assay technology. The company was founded in 1985 and is headquartered in Los Angeles, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.31 |
| Volume | 449840 |
| Volume Avg | (mio) 1.09 |
| 52 Week High | 1.06 |
| 52 Week Low | 0.24 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.05 |
| EPS change Q/Q | 1000% |
| EPS change Q/Q Yr ago | -500% |
| EPS change Q/Q next Q est | -50% |
| EPS change Y/Y | -60% |
| REV change Q/Q | 100% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | -0.04 |
| EPS next Y est | -0.15 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |